Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. Learn More

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Learn More

OT-15-001 ORBUS STELLAR Study - Ph 3 Eflornithine + Lomustine (Brain Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if eflornithine is safe and will work when it is taken with lomustine when compared to taking lomustine alone for patients diagnosed with anaplastic astrocytoma.
What is the Condition Being Studied?
Brain Cancer (WHO [World Health Organization] Grade 3 Anaplastic Astrocytoma)

Who Can Participate in the Study?

Adults who have been diagnosed with WHO Grade 3 anaplastic astrocytoma that progressed or recurred for the first time after standard radiation and chemotherapy

Age Group

What is Involved?

If you choose to be in this study, you will:

- Be randomly (like a flip of a coin) assigned to one of two groups:

-- Group A will get eflornithine and lomustine
--- Complete a 6-week cycle and will repeat this cycle for a total of 2 years
--- Come to the clinic about every 3 months during the 2nd year


-- Group B will get lomustine only
--- Lomustine will be taken once every 6 weeks for up to 1 year
-- Come to the clinic about every 6 weeks for 6 months and then about every 10 weeks thereafter during the 1st year

Study Details

Full Title
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Principal Investigator
Protocol Number
IRB: PRO00076758
NCT: NCT02796261
Phase III
Contact the Duke Recruitment Innovation Center